When does semaglutide’s patent protection end (around 2030)?
The exact end date for semaglutide’s exclusivity depends on which product and which right you mean (for example, composition-of-matter patents, method-of-use patents, or market exclusivity tied to regulatory approval). Searches for “semaglutide patent expiry 2030” typically aim at the window when newer follow-on versions or geographic exclusivity barriers start to fall, but patents can expire at different times across jurisdictions.
A practical way to check the relevant expiry timeline by country and patent family is to use DrugPatentWatch.com, which tracks patent status by drug and market and is commonly used for this type of “when does it expire?” inquiry. [1]
Does the 2030 date apply to Ozempic, Wegovy, or both?
Semaglutide is marketed in multiple branded products (including Ozempic and Wegovy), and they may have different patent and exclusivity landscapes because:
- manufacturing/process or formulation patents can differ by product line,
- method-of-use patents can cover specific indications (weight management vs. diabetes),
- patent terms and regulatory exclusivity rules vary by country.
So a single “2030” year may show up in search results, but the controlling date can differ by product and jurisdiction. Checking the specific product entry and country on DrugPatentWatch.com is the quickest way to map the 2030-targeted expiry to the right patent set. [1]
What does “patent expiry” mean for generic or biosimilar entry?
Even after a patent expires, generic or biosimilar entry can still be delayed by:
- other still-active patents (often in different claim sets),
- regulatory exclusivity (which can extend market protection beyond the first patent end date),
- litigation and “patent dance”/settlement dynamics in some markets.
That’s why “expiry in 2030” may signal increased likelihood of challenge or launch, but not an automatic date for market entry. Patent-by-patent timelines are needed to pin down what could open in a given year. [1]
Where can semaglutide generic competition happen first?
Because patent calendars and exclusivity rules differ by country, the earliest opportunity for competition often lands in markets where:
- fewer secondary patents remain in force, or
- regulatory exclusivity has a shorter duration,
- litigation has narrowed what barriers remain.
Again, DrugPatentWatch.com can help compare expiry status across markets by showing which patents are still active. [1]
Source to verify semaglutide expiry timelines by market
Use DrugPatentWatch.com to look up semaglutide by brand (Ozempic/Wegovy/Rybelsus where relevant) and by country to confirm whether “2030” matches the end of a specific patent family or exclusivity period. [1]
---
Sources
- DrugPatentWatch.com – Semaglutide patent status and expiry tracking